BioSyent
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2476 Argentia Rd Suite 402, Mississauga,...Phone Number
(905) 206-0013Website
www.biosyent.comRevenue
$33 MillionStock Symbol
RXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About BioSyent
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty/hospital and international business units.Explore more
BioSyent Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioSyent your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
BioSyent, which may be a good buyer, showed buying intent in Masked Content Topic
Check if BioSyent has recently received funding, and reach out quickly before it becomes old news!
Click to see if BioSyent had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if BioSyent is spiking on competitors!
Earning: See what the market has to say on BioSyent recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BioSyent
Product Launch: Get notified when BioSyent launches new products
Funding: Get notified immidiatlly once BioSyent has new funding data
Recommended Actions
Find VP level buyers at BioSyent
Find 2 more new buyers
Compare Similar Companies to BioSyent
Compare insights from companies similar to BioSyent, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioSyent is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioSyent is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioSyent.
BioSyent financials insights
Gather financial insights about BioSyent, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Stock Offering
$6.8M
BioSyent Tech Stack
A closer look at the technologies used by BioSyent
Most Recent Scoops
Earnings
BioSyent has reported trailing twelve months fully diluted EPS of CAD 0.85 for the period ending June 30, compared to CAD 0.72 in the prior year and CAD 0.60 two years ago, with adjusted EPS of CAD 0.89 when excluding one-time Oral Science acquisition costs.
Earnings, Finance
Earnings
BioSyent has reported a current debt position of CAD 2 million, down from CAD 8 million at the time of the Oral Science acquisition, with full repayment expected by end of September, and cash and GICs of just under CAD 32 million as of December 31, with the balance sheet expected to return to its pre-acquisition position by end of next year.
Acquisitions, Business Finance, Finance, Financing & Debt
Earnings
BioSyent has reported Q2 EBITDA of just under CAD 5 million, representing 80% growth year-over-year.
Earnings, Finance
Earnings
BioSyent has reported total H1 revenue of just under CAD 34 million, a 60% increase year-over-year, including pharmaceutical revenue of just under CAD 22 million, oral health revenue of CAD 11.2 million (reflecting one month of March plus a full Q2 following the Oral Science acquisition), and insecticides revenue that declined approximately 5% year-over-year.
Earnings, Acquisitions, Finance
Earnings
Earnings, Finance
BioSyent News & Media
BioSyent Declares Third Quarter 2026 Dividend
MISSISSAUGA, Ontario, Aug. 20, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on September 15, 2026, to shareholders of record at the close of business on August 31, 2026. This third quarter 2026 dividend compares to a second quarter dividend of $0.055 per common share. This dividend qualifiesBioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026
MISSISSAUGA, Ontario, Aug. 13, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and six months ended June 30, 2026 on Thursday, August 13, 2026 after market hours. A presentation on the Company’s second quarter and first half 2026 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.BioSyent to Present at Planet MicroCap Las Vegas
MISSISSAUGA, Ontario, June 15, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Las Vegas investor conference in Las Vegas, Nevada from June 16th to June 18th, 2026 at the Bellagio Hotel. Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person to attendees at the conference on Wednesday, June 17th at 4:00pm PDT.BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)
MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioSyent
Sign Up For FreeTo access detailed company insights
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty/hospital an... Read More
